Plus: Evvy.AI launches, trained on 100,000+ vaginal microbiome tests; three mental health innovators shortlisted; and the NHS urged to update website following PCOS rename to PMOS.
Cyclana Bio recruited the first patients for its 500-patient clinical observational PEMP study, offering femtech operators and clinicians new insights into endometriosis research. Healthcare innovation and terminology shifts are impacting women's health, as Evvy launched Evvy.AI for vaginal health, trained on over 100,000 microbiome tests, and PCOS was renamed PMOS, a condition affecting one in eight women. Five takes inside, plus a quick-hits roundup.
VIA FemTech World
Véa analyzed over 101,000 anonymized words journaled, identifying over 3,000 specific cognitive distortions like 'double-bind' guilt. HealCycle monitors HPO-axis markers and addresses conditions such as PMDD, integrating an AI companion, Tara. Môr developed a patented AM/PM chrono-targeted nutritional system to improve cognitive wellbeing based on women's brain function. Investors should note these innovations addressing previously overlooked aspects of women's mental and cognitive health.
Read the full story →
— The Luteal Editorial Team
VIA FemTech Insider
Cyclana Bio recruited the first patients for its 500-patient clinical observational PEMP study. The NHS Health Research Authority approved the study, which takes place at Peterborough City Hospital and Rosie Hospital, Cambridge. The PEMP study aims to uncover endometriosis causal mechanisms using human data and cells. This offers femtech operators and clinicians new insights into endometriosis research.
Read the full story →
— The Luteal Editorial Team
VIA FemTech Insider
Evvy launched EvvyAI, an AI advisor for vaginal health. This new tool, trained on over 100,000 vaginal microbiome tests, aims to address the approximately 60% failure rate of leading AI models on women's health questions. This development offers femtech operators a new pathway for personalized patient support.
Read the full story →
— The Luteal Editorial Team
VIA FemTech World
About one in eight women are affected by the condition formerly known as PCOS, which has been renamed PMOS, or polyendocrine metabolic ovarian syndrome. The announcement included a three-year transition period, and professional societies are currently informing members about the change. The UK National Institute for Health and Care Excellence (Nice) will publish the first standalone guidelines for PMOS/PCOS later this year.
Read the full story →
— The Luteal Editorial Team
VIA FemTech World
Only one percent of women can name all five gynaecological cancers. This knowledge gap contributes to 21 women in the UK dying daily from these diseases. Additionally, 31% of women avoid seeking medical advice for gynaecological symptoms, indicating a significant healthcare engagement challenge for femtech operators.
Read the full story →
— The Luteal Editorial Team